Details of the Drug Combination

General Information of Drug Combination (ID: DCP0J3R)

Drug Combination Name
Daidzin Phensuximide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Daidzin   DMFCMPS Phensuximide   DMFGLXB
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 0.57
Bliss Independence Score: 0.57
Loewe Additivity Score: 13.61
LHighest Single Agent (HSA) Score: 13.62

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Daidzin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mitochondrial aldehyde dehydrogenase (ALDH2) TTFLN4T ALDH2_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Daidzin Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [5]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Increases Expression [5]
------------------------------------------------------------------------------------
Indication(s) of Phensuximide
Disease Entry ICD 11 Status REF
Absence epilepsy N.A. Approved [2]
Epilepsy 8A60-8A68 Approved [2]
Seizure disorder 8A6Z Approved [3]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Phensuximide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7612).
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5 Intestinal bacteria activate estrogenic effect of main constituents puerarin and daidzin of Pueraria thunbergiana. Biol Pharm Bull. 2006 Dec;29(12):2432-5. doi: 10.1248/bpb.29.2432.